Received May 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
no adverse event; HCP calling to request information regarding GARDASIL 9. Request case 02800767. HCP reported a male patient received first dose of GARDASIL 9 on 9/14/2024, a second dose on 10/19/2024, and is currently requesting the 3rd dose. HCP reported that; HCP calling to request information regarding GARDASIL 9. Request case 02800767. HCP reported a male patient received first dose of GARDASIL 9 on 9/14/2024, a second dose on 10/19/2024, and is currently requesting the 3rd dose. HCP reported that; This spontaneous report was received from a Pharmacist and refers to a 46-year-old male patient. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 14-Sep-2024, the patient started therapy with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL9), 0.5 mL (lot # and expiration date were not reported)( Inappropriate age at vaccine administration). On 19-Oct-2024, the patient received second dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL9), 0.5 mL (lot # and expiration date were not reported) (Inappropriate age at vaccine administration). No adverse event was reported.